Earnings Call Insights: Nuvation Bio (NUVB) Q1 2026 Management View Dr. David Hung said the launch is being driven by steady demand and an improving mix toward earlier-line use: “We successfully treated approximately 200 new patients with IBTROZI in the first quarter, which makes 3 consecutive quarters of about 200 new patient starts, bringing our total to over 600 since launch.” He emphasized the...
Earnings Call Insights: Nuvation Bio (NUVB) Q1 2026 Management View Dr. David Hung said the launch is being driven by steady demand and an improving mix toward earlier-line use: “We successfully treated approximately 200 new patients with IBTROZI in the first quarter, which makes 3 consecutive quarters of about 200 new patient starts, bringing our total to over 600 since launch.” He emphasized the mix shift as a key commercial inflection: “for the first time since launch, more than half of the new patients who started IBTROZI in the quarter were TKI naive,” and linked it to “revenue stacking.” Hung highlighted updated durability data as commercial messaging, citing a new analysis: “IBTROZI has now extended its median duration of response to 50 months in TKI-naive patients in the pooled results from the pivotal TRUST studies.” He also pointed to NCCN CNS guideline inclusion: “We are also encouraged by the addition of IBTROZI to the latest CNS NCCN guidelines as a systemic therapy option for ROS1-positive NSCLC patients with brain metastases.” Colleen Sjogren framed adoption as broadening beyond academia and tied execution to awareness and account penetration: “aided awareness of IBTROZI among target physicians has reached 97%,” and “100% of the top 50 historical TKI accounts in the country have prescribed IBTROZI.” She reiterated management’s focus on raising community testing rates, noting some are “below 50% in some centers.” Philippe Sauvage summarized the quarter’s revenue mix and the shift toward longer-duration patients: “In the first quarter, we generated $83.2 million in total revenue, including $18.5 million in IBTROZI net U.S. product revenue.” He also disclosed collaboration revenue and royalties: “we recognized $64.7 million in collaboration and license revenue in the quarter, including an upfront payment of nearly $60 million from Eisai,” plus “approximately $1.7 million in royalty payments from our partnerships in Japan and China.” Outlook Management di...
Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Management View "I am so pleased that we completed the Amicus acquisition last week... with the addition of 2 innovative therapies, Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease." (President, CEO & Director Alexander Hardy) "The acquisition accelerates our anticipated year-over-year 2026 revenue growth to ...
Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Management View "I am so pleased that we completed the Amicus acquisition last week... with the addition of 2 innovative therapies, Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease." (President, CEO & Director Alexander Hardy) "The acquisition accelerates our anticipated year-over-year 2026 revenue growth to 20% at the midpoint of today's updated guidance." (President, CEO & Director Hardy) "We saw strong patient demand for VOXZOGO with new patient starts increasing across all regions in the first quarter." (President, CEO & Director Hardy) "Total revenues in the first quarter were $766 million" and "First quarter non-GAAP diluted earnings per share was $0.76." (CFO & Executive VP of Finance Brian Mueller) "Cost of sales increased year-over-year in the first quarter, primarily due to a $31 million charge associated with an unsuccessful process qualification campaign to extend NAGLAZYME manufacturing capabilities. Importantly, this did not impact commercial supply." (CFO & Executive VP of Finance Mueller) Outlook "We are raising Enzyme Therapies revenue guidance to a range of $2.725 billion to $2.775 billion for the full year 2026" and "increases our full year total revenue guidance to a range of $3.825 billion to $3.925 billion." (CFO & Executive VP of Finance Mueller) "For VOXZOGO, we are maintaining our revenue guidance of $975 million to $1.025 billion" and "On non-GAAP diluted earnings per share guidance, we are updating the guidance range to $4.85 to $5.05." (CFO & Executive VP of Finance Mueller) "To provide context, we expect more than 55% of total 2026 revenues to be recognized in the second half of the year" and "These earnings timing dynamics drive approximately 2/3 of our 2026 earnings per share expected in the second half of the year." (CFO & Executive VP of Finance Mueller) Financial Results "Total revenues in the first quarter were $766 million" and management sai...
(RTTNews) - Ahead of the long holiday weekend for Labor Day and Coronation Day, the Thai Stock market had moved higher in four straight sessions, adding almost 40 points or 2.7 percent along the way. The Stock Exchange of Thailand now sits just above the 1,490-point plateau altho
(RTTNews) - Ahead of the long holiday weekend for Labor Day and Coronation Day, the Thai Stock market had moved higher in four straight sessions, adding almost 40 points or 2.7 percent along the way. The Stock Exchange of Thailand now sits just above the 1,490-point plateau altho
As Hong Kong prepares for another major push in public works, one question deserves far more attention than it has received: are we buying infrastructure in a way that is sustainable for the construction industry and the public as a whole? In his February budget, Financial Secretary Paul Chan Mo-po announced that HK$150 billion (US$19.1 billion) will be transferred from the Exchange Fund to suppor...
As Hong Kong prepares for another major push in public works, one question deserves far more attention than it has received: are we buying infrastructure in a way that is sustainable for the construction industry and the public as a whole? In his February budget, Financial Secretary Paul Chan Mo-po announced that HK$150 billion (US$19.1 billion) will be transferred from the Exchange Fund to support the Northern Metropolis and other infrastructure projects in the coming two years. This major...
tadamichi/iStock via Getty Images April 2026 brought a broad recovery across asset classes, reversing much of March’s losses. U.S. stocks led the month at +10.51%, largely unwinding their -4.93% March decline and pushing their year-to-date return to +5.69%. U.S. real estate followed with an +8.53% gain, bringing its year-to-date total to +9.61%, while world stocks added +7.54%, extending their yea...
tadamichi/iStock via Getty Images April 2026 brought a broad recovery across asset classes, reversing much of March’s losses. U.S. stocks led the month at +10.51%, largely unwinding their -4.93% March decline and pushing their year-to-date return to +5.69%. U.S. real estate followed with an +8.53% gain, bringing its year-to-date total to +9.61%, while world stocks added +7.54%, extending their year-to-date gain to +9.70%. Commodities posted another positive month with a +6.64% gain in April, further extending their lead on the 2026 scoreboard. Through the end of April, commodities have returned +49.13% year-to-date, a wide margin ahead of every other asset class. Managed futures added +2.58% in April, marking their third positive month out of four in 2026. After a modest -0.83% dip in March, when most risk assets fell sharply, managed futures finished April with a +10.22% year-to-date gain, placing them second on the scoreboard behind commodities. Notably, managed futures have delivered positive returns in each month that risk assets broadly advanced while limiting losses during March’s downturn. Hedge funds gained +4.60% in April, bringing their year-to-date return to +6.50%. Bonds edged up just +0.15%, keeping their year-to-date return at a slim +0.20%, while cash continued its steady pace with another +0.31% for the month, now up +1.23% for the year. As April closes, every asset class on the 2026 scoreboard sits in positive territory. Commodities hold a commanding year-to-date lead, while managed futures remain in a clear second place, having navigated both the first-quarter volatility and April’s broad rebound while posting consistent positive results. Past performance is not indicative of future results. Past performance is not indicative of future results. Sources Managed Futures = SocGen CTA Index Cash = US T-Bill 13-week coupon equivalent annual rate/12, with YTD the sum of each month’s value Bonds = Vanguard Total Bond Market ETF ( BND ) Hedge Funds = IQ He...